Statements (28)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:chemical_compound
|
gptkbp:approvedBy |
gptkb:FDA
|
gptkbp:ATCCode |
N05CM25
|
gptkbp:CASNumber |
gptkb:347396-82-1
|
gptkbp:developedBy |
gptkb:Merck_&_Co.
|
gptkbp:hasMolecularFormula |
C23H23ClN6O2
|
gptkbp:hasSMILES |
CN1CCN(CC1)C(=O)C2=CC(=C(C=C2)C)N3N=CC=N3
|
gptkbp:hasUNII |
7XUQ444B8W
|
https://www.w3.org/2000/01/rdf-schema#label |
347396-82-1
|
gptkbp:IUPACName |
[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
|
gptkbp:KEGGID |
gptkb:D10366
|
gptkbp:legalStatus |
prescription only
|
gptkbp:marketedAs |
gptkb:Belsomra
|
gptkbp:mechanismOfAction |
orexin receptor antagonist
|
gptkbp:molecularWeight |
450.92 g/mol
|
gptkbp:name |
gptkb:Suvorexant
|
gptkbp:pregnancyCategory |
C (US)
|
gptkbp:PubChem_CID |
gptkb:CHEMBL2105757
DB09025 29341913 46215917 |
gptkbp:routeOfAdministration |
oral
|
gptkbp:sideEffect |
dizziness
headache somnolence |
gptkbp:usedFor |
treatment of insomnia
|
gptkbp:bfsParent |
gptkb:Lucentis
|
gptkbp:bfsLayer |
5
|